Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Total Liabilities (2019 - 2025)

Lyell Immunopharma's Total Liabilities history spans 7 years, with the latest figure at $78.8 million for Q3 2025.

  • For Q3 2025, Total Liabilities fell 10.93% year-over-year to $78.8 million; the TTM value through Sep 2025 reached $78.8 million, down 10.93%, while the annual FY2024 figure was $108.0 million, 13.63% up from the prior year.
  • Total Liabilities for Q3 2025 was $78.8 million at Lyell Immunopharma, down from $86.5 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $334.0 million in Q1 2021 and bottomed at $78.8 million in Q3 2025.
  • The 5-year median for Total Liabilities is $98.5 million (2023), against an average of $135.7 million.
  • The largest annual shift saw Total Liabilities plummeted 49.37% in 2023 before it grew 13.63% in 2024.
  • A 5-year view of Total Liabilities shows it stood at $197.6 million in 2021, then tumbled by 47.22% to $104.3 million in 2022, then fell by 8.85% to $95.1 million in 2023, then grew by 13.63% to $108.0 million in 2024, then dropped by 27.02% to $78.8 million in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Total Liabilities are $78.8 million (Q3 2025), $86.5 million (Q2 2025), and $93.3 million (Q1 2025).